Abstract:Polo-like kinase 1 (Plk1) belongs to a subfamily of Ser/ Thr protein kinases, collectively termed polo-like kinases (Plks). A growing body of evidence suggests that Plk1 plays important roles during multiple stages of M-phase progression and, as a result, in cell proliferation. In a series of preclinical studies, PLK1 has been validated as a cancer target. This has prompted many research scientists to develop selective PLK1 inhibitors for the treatment of cancer. The recent strategy employed in PLK1 inhibition involves the designing of small molecule inhibitors that targets the classical ATP-binding site of PLK1. Purpurogallin (PPG) and poloxin have been reported as inhibitors of the polo-box domain (PBD) of human polo-like kinase 1. Recently, new generation of PLK1 inhibitors targeting the second druggable domain of PLK1, the polo box domain, is currently being tested preclinically. We propose to design and develop 1, 3-thiazolidin-4-ones which could inhibit PLK1 for potent anticancer and anti-inflammatory activities. The 1, 3-thiazolidin – 4-ones could show anticancer and anti-inflammatory potential through inhibition of polo-like kinase 1 (PLK1) and cyclooxygenase-2 (COX 2) via NF-Kb (nuclear factor kappa-light- chain-enhancer of activated B cells) protein. Molecular docking of a set of ligands was performed using Vlife MDS 4.4 software. The 3D ligand protein complex structure of Polo Like Kinase 1 (2rku) was obtained from the protein database bank (RCSB-PDB) and processed for protein preparation and optimization. The computational studies suggest that aromatic group with non-polar electronegative substituents at second position and nitro-heterocycle either directly or through amide linkage at third position of the 1, 3-thiazolidin – 4-ones could result in better anticancer compound through inhibition of enzyme polo-like kinase 1.

Combined Pharmacophore Modeling, Docking, And 3d-Qsar Studies Of Plk1 Inhibitors

Exploring Novel PLK1 Inhibitors Based on Computational Studies of 2,4-Diarylaminopyrimidine Derivatives

De novo design of PLK1 inhibitors based on 2-amino aromatic heterocyclic scaffold: 3D-QSAR and molecular fragment replacement

Protein-based Alignment in 3D-QSAR of Polo-Like Kinase 4 Inhibitors

QSAR study of tetrahydropteridin derivatives as polo-like kinase 1(PLK1) Inhibitors with molecular docking and dynamics study

Identification of PLK1-PBD Inhibitors from the Library of Marine Natural Products: 3D QSAR Pharmacophore, ADMET, Scaffold Hopping, Molecular Docking, and Molecular Dynamics Study

Dynamic and Multi-Pharmacophore Modeling for Designing Polo-Box Domain Inhibitors

3D-QSAR and Docking Studies of 3-Pyridine Heterocyclic Derivatives As Potent PI3K/mTOR Inhibitors

3D-QSAR Studies, Molecular Docking, Molecular Dynamic Simulation, and ADMET Proprieties of Novel Pteridinone Derivatives as PLK1 Inhibitors for the Treatment of Prostate Cancer

Design of novel PLK4 inhibitors as TRIM37-amplified breast cancer drugs using 3D-QSAR, molecular docking, and molecular dynamics simulation methods

3D-QSAR, Docking, and Molecular Dynamics Simulations Studies on Quinazoline Derivatives As PAK4 Inhibitors

Molecular Docking and 3D-QSAR Studies on Checkpoint Kinase 1 Inhibitors

Structure-based discovery of 1-(3-fluoro-5-(5-(3-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)phenyl)-3-(pyrimidin-5-yl)urea as a potent and selective nanomolar type-II PLK4 inhibitor

3D-QSAR Modeling and Molecular Docking Study on Mer Kinase Inhibitors of Pyridine-Substituted Pyrimidines

Molecular Docking Studies of 1, 3- Thiazolidin-4-Ones as Potential Human Polo Like Kinase 1 (Plk 1) Inhibitors

Study on Pharmacokinetics and Metabolic Profiles of Novel Potential PLK-1 Inhibitors by UHPLC-MS/MS Combined with UHPLC-Q-Orbitrap/HRMS

Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110alpha inhibitors.

Discovery of a Potent PLK1-PBD Small-Molecule Inhibitor As an Anticancer Drug Candidate Through Structure-Based Design

D-QSAR studies on pyrimidine analogues as cyclin-dependent kinase 1 inhibitors

Molecular docking-based 3D-QSAR studies of pyrrolo[3,4-c]pyrazole derivatives as Aurora-A inhibitors

Kinase Domain Inhibitors of PLK1: SAR and Interaction Mode